Lead
On March 13, 2026, the American Heart Association and the American College of Cardiology updated U.S. cholesterol-management guidance, recommending broader prevention efforts and an initial, one-time lipoprotein(a) blood test for all adults. The guidance, issued jointly and published in Circulation and JACC, aims to expand risk assessment beyond LDL cholesterol and encourage earlier intervention when lifetime risk is elevated. The new framework also endorses wider use of coronary artery calcium scoring and a risk calculator called PREVENT to inform treatment timing. If adopted widely, the recommendations could shift many patients toward earlier lipid-lowering therapy.
Key Takeaways
- The AHA/ACC guidelines (13 March 2026) call for a one-time lipoprotein(a) test for all adults; lipoprotein(a) is genetically determined and usually stable across a lifetime.
- Coronary artery calcium (CAC) scoring is recommended more broadly as a noninvasive measure of calcified plaque to refine risk estimates and treatment decisions.
- The PREVENT tool is recommended to project a patient’s 10-year and 30-year cardiovascular risk and guide earlier medication use when lifetime risk is high.
- Statins remain the first-line pharmacologic therapy; guidelines allow earlier initiation for patients whose lifetime risk profile suggests benefit.
- An estimated 25% of U.S. adults have high LDL cholesterol, a major modifiable contributor to heart attacks and strokes.
- The guidance places greater weight on lifetime risk rather than short-term risk alone, a shift that could increase preventive treatment uptake.
Background
Cardiovascular disease remains the leading cause of death for men and women in the United States, driving repeated updates to prevention guidance. Historically, LDL cholesterol has been the dominant laboratory target for clinicians assessing atherosclerotic cardiovascular disease risk. Over the past decade, however, researchers and professional societies have added new biomarkers and imaging tools to refine risk estimates and personalize therapy.
Lipoprotein(a), often abbreviated Lp(a), has gained attention because high levels are inherited and confer additional risk for heart attacks and strokes independent of LDL. Despite its relevance, Lp(a) testing has not been routine in primary care, in part because the test was not explicitly recommended in many prior screening frameworks. The latest guidance responds to accumulating evidence and calls for clearer, more standardized use of Lp(a) in prevention planning.
Main Event
The American Heart Association and the American College of Cardiology released updated cholesterol-management guidelines on March 13, 2026, emphasizing earlier and more intensive prevention strategies. The panels recommend clinicians offer a one-time Lp(a) blood test to all adults, noting the test is simple, widely available, and usually needs to be done only once because genetic determinants keep levels relatively stable.
The guidelines also expand the role of coronary artery calcium scoring, a CT-based measure of calcified plaque, for people whose risk is uncertain or borderline. By combining biomarkers, imaging and tools like PREVENT — which projects 10-year and 30-year risk — clinicians are encouraged to take a longer view of a patient’s lifetime exposure to risk and consider earlier treatment when appropriate.
Roger Blumenthal of Johns Hopkins chaired the writing committee and emphasized that LDL remains a critical target but that additional metrics can produce a fuller risk profile. The guidance keeps statins as the primary drug therapy for lowering LDL, while saying that medication can be appropriate even for some patients with modest near-term risk if long-term risk is high.
Practicing cardiologists reacted that the guidance represents a material change in approach. Dr. Steven Nissen of the Cleveland Clinic described the shift toward lifetime risk as a major reorientation in preventive practice and predicted the recommendations will increase the number of people started on statins and other LDL-lowering medicines.
Analysis & Implications
Operationalizing a one-time Lp(a) test for all adults would alter screening workflows in primary care and cardiology clinics. Because Lp(a) is stable and genetically determined, a single measurement early in adulthood can stratify lifelong inherited risk and prompt earlier lifestyle or pharmacologic interventions for those at higher inherited risk.
Broader use of CAC scoring and the PREVENT calculator will likely reduce clinical uncertainty for patients who fall into intermediate risk categories today. For some patients, a high lifetime-risk estimate or a positive CAC score will tip the balance toward starting statins sooner, changing the timing of therapy from reactive to proactive prevention.
Health systems and payers will face implementation questions: coverage policies for routine Lp(a) testing, access to CAC scans, and reimbursement for expanded risk assessment tools. In settings with constrained imaging capacity, wider CAC use could create bottlenecks, while routine Lp(a) testing — a simple blood test — may be more scalable if payers support it.
Population-level effects depend on uptake. If millions more people are identified and treated earlier, modelers project reductions in heart attacks and strokes over decades; however, the magnitude of benefit will depend on adherence, equitable access, and whether additional targeted therapies for Lp(a) emerge and prove effective.
Comparison & Data
| Test/Tool | What it measures | When to use | Clinical action triggered |
|---|---|---|---|
| LDL cholesterol | Circulating low-density lipoprotein | Routine lipid panels | Statin consideration if elevated |
| Lipoprotein(a) | Genetically determined lipoprotein particle | One-time in adulthood (per new guidance) | Signals inherited risk; may prompt earlier therapy |
| Coronary artery calcium (CAC) | Calcified plaque in coronary arteries (CT) | When risk is uncertain or intermediate | Refine risk; can justify starting statins |
| PREVENT tool | 10- and 30-year risk projection | Risk discussion and long-term planning | Helps decide on timing of medications |
The table summarizes roles each test or tool plays under the new framework: Lp(a) for inherited lifetime risk, CAC for imaging evidence of plaque, LDL for modifiable exposure, and PREVENT for long-horizon risk projections.
Reactions & Quotes
Guideline authors and clinicians framed the changes as an effort to provide a fuller, lifetime-oriented prevention strategy.
“Measuring additional biomarkers gives a more complete picture of cardiovascular risk and can inform earlier treatment decisions,”
Roger Blumenthal, Johns Hopkins (guideline committee chair)
Practicing cardiologists stressed the shift toward lifetime risk and the likelihood that more patients will be started on preventive medicines.
“Focusing on a person’s lifetime risk is a major change that will lead to more people being treated earlier,”
Dr. Steven Nissen, Cleveland Clinic
Guideline writers reiterated that lifestyle measures remain central even as testing expands.
“Diet, exercise and avoiding tobacco are the cornerstone of cardiac prevention,”
Dr. Leslie Cho, Cleveland Clinic
Unconfirmed
- The precise number of additional patients who will begin statin therapy as a direct result of these recommendations is not yet quantified and will depend on clinician uptake and payer coverage.
- Long-term population-level reductions in heart attacks and strokes from routine Lp(a) testing and earlier treatment remain projected rather than measured; outcomes data will take years to accrue.
- The timeline and coverage decisions for any future Lp(a)-specific therapies are evolving and were not defined in the guideline release.
Bottom Line
The March 13, 2026 AHA/ACC cholesterol guidelines mark a shift toward broader and earlier cardiovascular prevention by recommending a one-time Lp(a) test for adults, more use of coronary calcium scoring, and application of the PREVENT lifetime-risk tool. Clinicians are encouraged to look beyond short-term LDL-based risk and consider lifetime exposure when deciding whether to start lipid-lowering therapy.
For patients, this means a simple blood test could reveal inherited risk that changes follow-up and treatment timing; for health systems, the recommendations raise practical questions about testing access, imaging capacity, and insurance coverage. Over the coming years, uptake, payer response and outcomes data will determine how much these changes reduce heart attacks and strokes at the population level.
Sources
- NPR — news reporting on guideline release (media)
- Circulation — peer-reviewed journal publishing the guideline (academic journal)
- Journal of the American College of Cardiology (JACC) — academic journal publishing guideline material (academic journal)
- American Heart Association (AHA) — professional medical organization and guideline co-author (official)
- American College of Cardiology (ACC) — professional medical organization and guideline co-author (official)